Health
NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali – – pharmaphorum
NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for previously treated breast cancer patients….
NICE has recommended moving Novartis Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients.
In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since 2019 until further trial data emerged addressing uncertainties about overall survival and cost-effectiveness.
These data are now available from the phase 3 MONALEESA-3, a randomised…
-
Noosa News23 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
General22 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity
-
General19 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank
-
General12 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore